22 mar: Novo Nordisk/Deutsche: Sænker anbefaling til "sælg"
22 mar: ECB kan droppe krisefond på 40 mia. euro - avis
22-03-2012 08:20:51

Dräger buys back 41.1 percent of participation certificates

Drägerwerk AG & Co. KGaA /

Dräger buys back 41.1 percent of participation certificates

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

Lübeck - Drägerwerk AG & Co. KGaA has bought back 41.1 percent of its issued participation certificates and now intends to redeem the purchased participation certificates. The participation certificates bought back have a total purchase price of EUR 122.1 million. This transaction decreases the equity ratio by about three percentage points; earnings per share on imputed actual full distribution will improve by 19 percent (based on the consolidated group financial statement 2011).

Improved capital structure

"Thanks to the successful buy-back, we have come a great deal closer to our goal of improving our capital structure. As such, we would like to thank all participation certificate holders that have accepted our offer," says Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG.

Premium for participation certificate holders was 26 percent

On February 15, 2012, Dräger requested that holders of participation certificate series A, K and D (series A: ISIN DE0005550651, WKN 555065; series K: ISIN DE0005550677, WKN 555067; series D: ISIN DE0005550719, WKN 555071) offer Dräger their participation certificates at a price of EUR 210 per share. The buy-back price named by Dräger corresponded to a premium of 26 percent on the average participation certificate price in the three months prior to the offer on February 15, 2012.

Disclaimer

This press release contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, Dräger does not assume any obligation to update the forward-looking statements contained in this report. Please go to Investor Relations / Financial Calendar at www.draeger.com for information on all important financial dates.

Contact

Corporate Communications:

Melanie Kamann

Tel. +49 451 882-3998

melanie.kamann@draeger.com

Investor Relations:

Vanina Hoffmann

Tel. +49 451 882-2685

vanina.hoffmann@draeger.com

Drägerwerk AG & Co. KgaA

Moislinger Allee 53-55

23542 Lübeck, Germany

www.draeger.com

Press release (PDF)


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

HUG#1596398

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
14 dec
GEN
Genmab kom sent fredag med en fondbørsmeddelse om en milestone på $3 milloner vedrørende deres DuoBo..
30
12 dec
OW
  Mange danske har nok set DR’s dokumentar udsendelser om, hvad der skete med mange af de tidligere ..
18
14 dec
VWS
Lomborg ved udmærket godt han er på gyngende grund, i mange af hans påstande.   Den værste er, når h..
16
13 dec
VWS
Nu kører vi/Vestas den sidste måned af Q4-2014, og aktiviteten er øget måned efter måned igennem 201..
16
14 dec
MAERSK-B
Husk nu at en produktions nedgang på små 500000 tønder om dagen kan få prisen til at stige markant m..
12
15 dec
GEN
Genmab har afholdt bestyrelsesmøde og valgt at give bestyrelse, direktion og ledende medarbejdere op..
11
14 dec
VWS
Der fik du godt nok sat alle verdens videnskabsfolk på plads! Rundt regnet 98% af alle de kloge, ans..
11
11 dec
 
Til dem af jer der shorter nordiske olie-aktier så er her shorting status på alle dem jeg har adgang..
10
12 dec
VWS
Interessant lille citat   "Netop nu knokler -ansatte på livet løs i det, der er vindmøllegigantens t..
9
17 dec
VWS
Det er meget interessant at Goldman Sachs øger sit target. Igår faldt Vestas 5 % alt imens et af ..
8

Novozymes vil ind på markedet for probiotika til foder - avis

17-12-2014 16:03:21
Novozymes har planer om at gøre sin entre på markedet for probiotika til dyrefoder, som selskabet ser gode muligheder i. Håbet er, at landbruget med tiden tager..

Bayer indsender FDA-registreringsansøgning for bløderprodukt

17-12-2014 14:05:05
Den tyske virksomhed Bayer Healthcare har indsendt registreringsansøgning for lægemiddelkandidaten BAY 81-8973 til behandling af blødersygdommen Hæmofili A hos ..

Aktier/middag: Syv dages nedtur afløst af nervøse plusser

17-12-2014 11:32:52
Efter syv handelsdage i streg ser det danske aktiemarked ud til at have ramt sin foreløbige bund, og onsdag formiddag går det således atter let fremad for de da..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas: USA's senat godkender PTC-forlængelse
2
Aktier/tendens: Carlsberg og Vestas i fokus i nervøst marked
3
Ruslands regering sælger aktiver for at støtte rubel - NY
4
Direktør fyres for at give penge til håndboldklub
5
Aktier/middag: Syv dages nedtur afløst af nervøse plusser

Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. december 2014 05:03:11
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141211.1 - EUROWEB4 - 2014-12-18 05:03:11 - 2014-12-18 05:03:11 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x